(2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide

C164H209N15O31S4 — CID 157475731

About (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide

(2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide (PubChem CID 157475731) has the molecular formula C164H209N15O31S4 and a molecular weight of 3014.82 g/mol. Its IUPAC name is (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide.

Molecular Properties

• Compound Name: (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide
• PubChem CID: 157475731
• Molecular Formula: C164H209N15O31S4
• Molecular Weight: 3014.82 g/mol
• Exact Mass: 3012.41
• IUPAC Name: (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide
• SMILES: COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N(C)C)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N)o2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N3CCC3)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N3CCCC3)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1
• InChI: InChI=1S/C35H45N3O6S.C34H43N3O6S.C33H43N3O6S.C31H39N3O7.C31H39N3O6S/c1-23(16-27(39)20-29-21-36-34(45-29)38-14-6-7-15-38)33(42)37-30(18-25-10-12-28(43-3)13-11-25)31(40)19-26(17-24-8-4-5-9-24)32(41)35(2)22-44-35;1-22(15-26(38)19-28-20-35-33(44-28)37-13-6-14-37)32(41)36-29(17-24-9-11-27(42-3)12-10-24)30(39)18-25(16-23-7-4-5-8-23)31(40)34(2)21-43-34;1-21(14-25(37)18-27-19-34-32(43-27)36(3)4)31(40)35-28(16-23-10-12-26(41-5)13-11-23)29(38)17-24(15-22-8-6-7-9-22)30(39)33(2)20-42-33;2*1-19(12-23(35)16-25-17-33-30(32)41-25)29(38)34-26(14-21-8-10-24(39-3)11-9-21)27(36)15-22(13-20-6-4-5-7-20)28(37)31(2)18-40-31/h8,10-13,21,23,26,30H,4-7,9,14-20,22H2,1-3H3,(H,37,42);7,9-12,20,22,25,29H,4-6,8,13-19,21H2,1-3H3,(H,36,41);8,10-13,19,21,24,28H,6-7,9,14-18,20H2,1-5H3,(H,35,40);2*6,8-11,17,19,22,26H,4-5,7,12-16,18H2,1-3H3,(H2,32,33)(H,34,38)/t23-,26-,30+,35-;22-,25-,29+,34-;21-,24-,28+,33-;2*19-,22-,26+,31-/m11111/s1
• InChIKey: BVOMMNTZEIOJON-YQMIHETOSA-N
• XLogP: 21.83
• TPSA: 649.70 Ų
• H-Bond Donors: 7
• H-Bond Acceptors: 45
• Rotatable Bonds: 83
• Heavy Atoms: 214
• Complexity: —

Lipinski Rule of Five

4 violations

Rule	Value
MW ≤ 500	3014.82
LogP ≤ 5	21.83
H-Bond Donors ≤ 5	7
H-Bond Acceptors ≤ 10	45

Computed Properties (RDKit)

• Structural Alerts: {'alert_name': 'isolated_alkene', 'substructure': 'N/A'}, {'alert_name': 'Three-membered_heterocycle', 'substructure': 'N/A'}

Frequently Asked Questions

What is the IUPAC name of (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide?

The IUPAC name of (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide (CID 157475731) is (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide.

What is the SMILES notation for (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide?

The canonical SMILES for (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide is COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N(C)C)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N)o2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N3CCC3)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.COc1ccc(C[C@H](NC(=O)[C@H](C)CC(=O)Cc2cnc(N3CCCC3)s2)C(=O)C[C@@H](CC2=CCCC2)C(=O)[C@@]2(C)CO2)cc1.

What is the InChIKey of (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide?

The InChIKey is BVOMMNTZEIOJON-YQMIHETOSA-N. The full InChI is InChI=1S/C35H45N3O6S.C34H43N3O6S.C33H43N3O6S.C31H39N3O7.C31H39N3O6S/c1-23(16-27(39)20-29-21-36-34(45-29)38-14-6-7-15-38)33(42)37-30(18-25-10-12-28(43-3)13-11-25)31(40)19-26(17-24-8-4-5-9-24)32(41)35(2)22-44-35;1-22(15-26(38)19-28-20-35-33(44-28)37-13-6-14-37)32(41)36-29(17-24-9-11-27(42-3)12-10-24)30(39)18-25(16-23-7-4-5-8-23)31(40)34(2)21-43-34;1-21(14-25(37)18-27-19-34-32(43-27)36(3)4)31(40)35-28(16-23-10-12-26(41-5)13-11-23)29(38)17-24(15-22-8-6-7-9-22)30(39)33(2)20-42-33;2*1-19(12-23(35)16-25-17-33-30(32)41-25)29(38)34-26(14-21-8-10-24(39-3)11-9-21)27(36)15-22(13-20-6-4-5-7-20)28(37)31(2)18-40-31/h8,10-13,21,23,26,30H,4-7,9,14-20,22H2,1-3H3,(H,37,42);7,9-12,20,22,25,29H,4-6,8,13-19,21H2,1-3H3,(H,36,41);8,10-13,19,21,24,28H,6-7,9,14-18,20H2,1-5H3,(H,35,40);2*6,8-11,17,19,22,26H,4-5,7,12-16,18H2,1-3H3,(H2,32,33)(H,34,38)/t23-,26-,30+,35-;22-,25-,29+,34-;21-,24-,28+,33-;2*19-,22-,26+,31-/m11111/s1.

What are the key properties of (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide?

(2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide has a molecular weight of 3014.82 g/mol, XLogP of 21.83, 83 rotatable bonds, 7 hydrogen bond donors, and 45 hydrogen bond acceptors.

Where does this data come from?

All data for (2R)-5-(2-amino-1,3-oxazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-(2-amino-1,3-thiazol-5-yl)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-5-[2-(azetidin-1-yl)-1,3-thiazol-5-yl]-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-5-[2-(dimethylamino)-1,3-thiazol-5-yl]-2-methyl-4-oxopentanamide;(2R)-N-[(2S,5R)-5-(cyclopenten-1-ylmethyl)-1-(4-methoxyphenyl)-6-[(2R)-2-methyloxiran-2-yl]-3,6-dioxohexan-2-yl]-2-methyl-4-oxo-5-(2-pyrrolidin-1-yl-1,3-thiazol-5-yl)pentanamide is sourced from PubChem (CID 157475731), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).